• -
  • English
  • Japanese
  • Korean
市場調查報告書
商品編碼
1065764

異常血紅素症的全球市場:產業趨勢，佔有率，規模，成長，機會，預測(2022年∼2027年)

Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
出版日期: | 出版商: IMARC Services Private Limited | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球異常血紅素症的市場規模，2021年為83億6,000萬美金，預計2022年∼2027年之間以9.50％的年複合成長率成長，至2027年達到148億美元。

推動市場成長的主因是鐮狀細胞貧血(SCD)和地中海型貧血等各種病理的盛行率增加，及老年人口的貧血盛行率上升。還有醫療產業的大幅度擴大，促進研究開發(R&D)活動的各種政府的配合措施，預計促進市場成長。

本報告提供全球異常血紅素症市場相關調查分析，市場概要，各市場區隔、各地區的市場分析，競爭情形，企業簡介等資訊。

目錄

第1章 序文

第2章 範圍與調查手法

第3章 摘要整理

第4章 簡介

第5章 全球異常血紅素症市場

  • 市場概要
  • 市場成果
  • COVID-19影響

第6章 市場明細:各類型

  • 地中海型貧血
    • 主要市場區隔
  • 鐮狀細胞貧血
  • 其他

第7章 市場明細:各治療

  • 輸血
  • 幹細胞移植
  • 止痛藥
  • 抗生素
  • ACE抑制劑
  • 羥基脲
  • 其他

第8章 市場明細:試驗各類型

  • 紅血球(RBC)點數
  • 遺傳基因檢驗
  • 高效液相層析(HPLC)
  • 血紅素等電點電泳(Hb IEF)
  • 血紅素電泳(Hb ELP)
  • 血紅素溶度實驗

第9章 市場明細:各終端用戶

  • 醫院、診所
  • 臨床檢驗室
  • 其他

第10章 市場明細:各地區

  • 北美
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 南美
    • 巴西
    • 墨西哥
    • 其他
  • 中東、非洲
    • 市場明細:各國

第11章 SWOT分析

第12章 價值鏈分析

第13章 波特的五力分析

第14章 價格分析

第15章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Bio-Rad Laboratories Inc.
    • bluebird bio Inc.
    • Bristol-Myers Squibb Company
    • Danaher Corporation
    • Emmaus Life Sciences Inc.
    • Gamida-Cell Ltd.
    • Global Blood Therapeutics Inc.
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Prolong Pharmaceuticals LLC
    • Sangamo Therapeutics Inc.
    • Sysmex Corporation
目錄
Product Code: SR0322A34_Report

The global hemoglobinopathies market reached a value of US$ 8.36 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 14.8 Billion by 2027 exhibiting a CAGR of 9.50% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.

Hemoglobinopathies Market Trends:

  • The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

  • Thalassemia
  • Alpha Thalassemia
  • Beta Thalassemia
  • Sickle Cell Disease
  • Others

Breakup by Treatment:

  • Blood Transfusion
  • Stem-cell Transplantation
  • Analgesics
  • Antibiotics
  • ACE Inhibitors
  • Hydroxyurea
  • Others

Breakup by Test Type:

  • Red Blood Cell (RBC) Count
  • Genetic Testing
  • High Performance Liquid Chromatography (HPLC)
  • Hemoglobin Isoelectric Focusing (Hb IEF)
  • Hemoglobin Electrophoresis (Hb ELP)
  • Hemoglobin Solubility Test

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation. Key Questions Answered in This Report:

  • How has the global hemoglobinopathies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hemoglobinopathies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the treatment?
  • What is the breakup of the market based on the test type?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hemoglobinopathies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemoglobinopathies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Thalassemia
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alpha Thalassemia
      • 6.1.2.2 Beta Thalassemia
    • 6.1.3 Market Forecast
  • 6.2 Sickle Cell Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 Blood Transfusion
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Stem-cell Transplantation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Analgesics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibiotics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 ACE Inhibitors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Hydroxyurea
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Red Blood Cell (RBC) Count
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Genetic Testing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 High Performance Liquid Chromatography (HPLC)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hemoglobin Electrophoresis (Hb ELP)
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Hemoglobin Solubility Test
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bio-Rad Laboratories Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 bluebird bio Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emmaus Life Sciences Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gamida-Cell Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Global Blood Therapeutics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 PerkinElmer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Prolong Pharmaceuticals LLC
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Sangamo Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
  • Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion US$), 2016-2021
  • Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion US$), 2022-2027
  • Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2021
  • Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2021
  • Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2021
  • Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2021
  • Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2021
  • Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million US$), 2016 & 2021
  • Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2021
  • Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2022-2027
  • Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
  • Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
  • Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2021 and 2027
  • Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million US$), 2022-2027
  • Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million US$), 2022-2027
  • Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million US$), 2022-2027
  • Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million US$), 2022-2027
  • Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million US$), 2022-2027
  • Table 7: Global: Hemoglobinopathies Market: Competitive Structure
  • Table 8: Global: Hemoglobinopathies Market: Key Players